Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
VYNE Therapeutics Inc. (VYNE) had Return on Tangible Equity of -23.14% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$0.17M |
|
$-7.28M |
|
-- |
|
$0.17M |
|
$7.96M |
|
$-7.79M |
|
$0.37M |
|
$-7.43M |
|
$-7.43M |
|
$-7.43M |
|
$-7.43M |
|
$-7.28M |
|
$-7.43M |
|
$-7.79M |
|
$-7.94M |
|
42.80M |
|
42.80M |
|
$-0.17 |
|
$-0.17 |
|
| Balance Sheet Financials | |
$35.89M |
|
$0.10M |
|
$0.25M |
|
$36.13M |
|
$4.04M |
|
-- |
|
-- |
|
$4.04M |
|
$32.09M |
|
$32.09M |
|
$32.09M |
|
31.77M |
|
| Cash Flow Statement Financials | |
$-29.36M |
|
$28.91M |
|
$-0.13M |
|
$19.93M |
|
$19.35M |
|
$-0.58M |
|
$1.78M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.87 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-4610.65% |
|
-4610.65% |
|
-- |
|
-4394.08% |
|
-4307.69% |
|
$-29.36M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-23.14% |
|
|
Return on Tangible Equity |
-23.14% |
-20.55% |
|
-23.14% |
|
$1.01 |
|
$-0.69 |
|
$-0.69 |
|